1
|
Ge Z, Chandrasekhar J, Mehran R. Use of Bivalirudin for Anticoagulation in Interventional Cardiovascular Procedures. CARDIOVASCULAR INNOVATIONS AND APPLICATIONS 2018. [DOI: 10.15212/cvia.2017.0045] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022] Open
|
2
|
Van De Car DA, Rao SV, Ohman EM. Bivalirudin: a review of the pharmacology and clinical application. Expert Rev Cardiovasc Ther 2014; 8:1673-81. [DOI: 10.1586/erc.10.158] [Citation(s) in RCA: 38] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
|
3
|
Singh M, Adigopula S, Patel P, Kiran K, Khosla S. Recent advances in oral anticoagulation for atrial fibrillation. Ther Adv Cardiovasc Dis 2010; 4:395-407. [DOI: 10.1177/1753944710386844] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/17/2022] Open
Abstract
Atrial fibrillation is the most common sustained rhythm disturbance. Thromboembolic events related to atrial fibrillation result in significant morbidity, mortality and increases in the cost of healthcare. Anticoagulants are pivotal agents for the prevention and treatment of thromboembolic disorders. The latest American College of Cardiology/American Heart Association guidelines recommend antithrombotic therapy to prevent thromboembolism for all patients with atrial fibrillation, except those with lone atrial fibrillation or contraindications. Vitamin K antagonists were first synthesized in 1948 and for the past six decades they have been the only agents used for long-term oral anticoagulant therapy. Although these drugs are effective, they have numerous limitations, which have led to the development of newer anticoagulant therapies. The emerging oral anticoagulant agents are target selective. They have predictable pharmacokinetic and pharmacodynamic parameters and do not require routine monitoring. They are not associated with significant food and drug interactions, and can be administered in simple fixed daily or twice daily doses. This article reviews the current literature on various targets for anticoagulant therapy and newer oral anticoagulants for atrial fibrillation.
Collapse
Affiliation(s)
- Mukesh Singh
- Department of Cardiology, Mount Sinai Hospital, 1500 California Avenue, Chicago, IL 60608, USA,
| | | | - Pawan Patel
- Department of Cardiology, Mount Sinai Hospital, Chicago, IL, USA
| | - Kranti Kiran
- Department of Cardiology, Mount Sinai Hospital, Chicago, IL, USA
| | - Sandeep Khosla
- Department of Cardiology, Mount Sinai Hospital, Chicago, IL, USA
| |
Collapse
|